Inflammatory cytokine-specific alterations in retinal endothelial cell function

Microvascular Research

Volumn 89, Issue , 2013, Pages 57-69

  Palenski, Tammy L ^a   Sorenson, Christine M ^a   Sheibani, Nader ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; COLLAGEN TYPE 4; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRATE; NITRITE; OSTEOPONTIN; REACTIVE OXYGEN METABOLITE; TENASCIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RETINA CAPILLARY; RETINA CELL; RETINAL ENDOTHELIAL CELL;

DIABETIC RETINOPATHY; DR; EC; ECM; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; IL-1Β; INTERLEUKIN1-BETA; MCP-1; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TNF-Α; TUMOR NECROSIS-FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANIMALS; ANTIGENS, CD; APOPTOSIS; CADHERINS; CELL SURVIVAL; COLLAGEN TYPE IV; CYTOKINES; ENDOTHELIAL CELLS; INFLAMMATION; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; MICROCIRCULATION; NF-KAPPA B; OSTEOPONTIN; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RETINA; SIGNAL TRANSDUCTION; TENASCIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 84883169988     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2013.06.007     Document Type: Article

References (56)

1. Aiello L.P., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris F.L., Klein R. Diabetic retinopathy. Diabetes Care 1998, 21:143-156.
2. Amin R.H., Frank R.N., Kennedy A., Eliott D., Puklin J.E., Abrams G.W. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 1997, 38:36-47.
3. Aveleira A., Lin C.-M., Abcouwer S.F., Ambro F. TNF-a signals through PKCz/NF-kB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes 2010, 59:2872-2882.
4. Bartoli M., Platt D., Lemtalsi T., Gu X., Brooks S.E., Marrero M.B., Caldwell R.B. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003, 17:1562-1564.
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
6. Castellon R., Caballero S., Hamdi H.K., Atilano S.R., Aoki A.M., Tarnuzzer R.W., Kenney M.C., Grant M.B., Ljubimov A.V. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest. Ophthalmol. Vis. Sci. 2002, 43:2758-2766.
7. Chen Z., Han Z.C. STAT3: a critical transcription activator in angiogenesis. Med. Res. Rev. 2008, 28:185-200.
8. Chen C.-L., Liang C.-M., Chen Y.-H., Tai M.-C., Lu D.-W., Chen J.-T. Glucosamine modulates TNF-α-induced ICAM-1 expression and function through O-linked and N-linked glycosylation in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2012, 53:2281-2291.
9. Chistiakov D.A. Diabetic retinopathy: pathogenic mechanisms and current treatments. Diabetes Metab. Syndr. 2012, 5:165-172.
10. Darland D.C., D'Amore P.A. Cell-cell interactions in vascular development. Curr. Top. Dev. Biol. 2001, 52:107-149.
11. Du Y., Smith M.A., Miller C.M., Kern T.S. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J. Neurochem. 2002, 80:771-779.
12. El-Remessy A.B., Behzadian M.A., Abou-Mohamed G., Franklin T., Caldwell R.W., Caldwell R.B. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am. J. Pathol. 2003, 162:1995-2004.
13. Frank R.N. Diabetic retinopathy. N. Engl. J. Med. 2004, 350:48-58.
14. Frey T., Antonetti D.A. Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species. Antioxid. Redox Signal. 2011, 15:1271-1284.
15. Fruttiger M. Development of the retinal vasculature. Angiogenesis 2007, 10:77-88.
16. Gardner T.W., Antonetti D.A. A prize catch for diabetic retinopathy. Nat. Med. 2007, 13:131-132.
17. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107:1058-1070.
18. Gologorsky D., Thanos A., Vavvas D. Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy. Mediators Inflamm. 2012, 2012:629452.
19. Hammes H.-P., Feng Y., Pfister F., Brownlee M. Diabetic retinopathy: targeting vasoregression. Diabetes 2011, 60:9-16.
20. Hartsock A., Nelson W.J. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim. Biophys. Acta 2008, 1778:660-669.
21. Hartsock A., Nelson W.J. Competitive regulation of E-cadherin juxtamembrane domain degradation by p120-catenin binding and Hakai-mediated ubiquitination. PLoS One 2012, 7:e37476.
22. Huang Q., Sheibani N. High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am. J. Physiol. Cell Physiol. 2008, 295:C1647-C1657.
23. Ibrahim A.S., El-Shishtawy M.M., Peña A., Liou G.I. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol. Vis. 2010, 16:2033-2042.
24. Joussen A.M., Poulaki V., Le M.L., Koizumi K., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T.S., Adamis A.P. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004, 18:1450-1452.
25. Joussen A.M., Doehmen S., Le M.L., Koizumi K., Radetzky S., Krohne T.U., Poulaki V., Semkova I., Kociok N. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 2009, 15:1418-1428.
26. Kant S., Swat W., Zhang S., Zhang Z.-Y., Neel B.G., Flavell R.A., Davis R.J. TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev. 2011, 25:2069-2078.
27. Kern T.S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 2007:95103.
28. Kibbe M., Billiar T., Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc. Res. 1999, 43:650-657.
29. Kim Y.-W., West X.Z., Byzova T.V. Inflammation and oxidative stress in angiogenesis and vascular disease. J. Mol. Med. (Berl. Ger.) 2013, 91:323-328.
30. Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011, 437:169-183.
31. Kowluru R.A., Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest. Ophthalmol. Vis. Sci. 2004, 45:4161-4166.
32. Ljubimov A.V., Burgeson R.E., Butkowski R.J., Couchman J.R., Zardi L., Ninomiya Y., Sado Y., Huang Z.S., Nesburn A.B., Kenney M.C. Basement membrane abnormalities in human eyes with diabetic retinopathy. J. Histochem. Cytochem. 1996, 44:1469-1479.
33. Lu P., Li L., Liu G., Baba T., Ishida Y., Nosaka M., Kondo T., Zhang X., Mukaida N. Critical role of TNF-α-induced macrophage VEGF and iNOS production in the experimental corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 2012, 53:3516-3526.
34. Lund S.A., Giachelli C.M., Scatena M. The role of osteopontin in inflammatory processes. J. Cell Commun. Signal. 2009, 3:311-322.
35. Luo Y., Radice G.L. N-cadherin acts upstream of VE-cadherin in controlling vascular morphogenesis. J. Cell Biol. 2005, 169:29-34.
36. Mitamura Y., Takeuchi S., Ohtsuka K., Matsuda A., Hiraiwa N., Kusakabe M. Tenascin-C levels in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care 2002, 25:1899.
37. Murata T., Nakagawa K., Khalil A., Ishibashi T., Inomata H., Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab. Invest. 1996, 74:819-825.
38. Nawaz M.I., Van Raemdonck K., Mohammad G., Kangave D., Van Damme J., Abu El-Asrar A.M., Struyf S. Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy. Exp. Eye Res. 2013, 109:67-76.
39. Nehmé A., Edelman J. Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest. Ophthalmol. Vis. Sci. 2008, 49:2030-2038.
40. Oh I.K., Kim S.-W., Oh J., Lee T.S., Huh K. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr. Eye Res. 2010, 35:1116-1127.
41. Oshitari T., Yamamoto S., Hata N., Roy S. Mitochondria- and caspase-dependent cell death pathway involved in neuronal degeneration in diabetic retinopathy. Br. J. Ophthalmol. 2008, 92:552-556.
42. Provis J.M., Leech J., Diaz C.M., Penfold P.L., Stone J., Keshet E. Development of the human retinal vasculature: cellular relations and VEGF expression. Exp. Eye Res. 1997, 65:555-568.
43. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., Oppenheim J.J., Murphy W.J. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
44. Sheibani N., Sorenson C.M., Cornelius L.A., Frazier W.A. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem. Biophys. Res. Commun. 2000, 267:257-261.
45. Sottile J., Chandler J. Fibronectin matrix turnover occurs through a caveolin-1-dependent process. Mol. Biol. Cell 2005, 16:757-768.
46. Stratman A.N., Schwindt A.E., Malotte K.M., Davis G.E. Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Blood 2010, 116:4720-4730.
47. Su X., Sorenson C.M., Sheibani N. Isolation and characterization of murine retinal endothelial cells. Mol. Vis. 2003, 9:171-178.
48. Tan Y., Ichikawa T., Li J., Si Q., Yang H., Chen X., Goldblatt C.S., Meyer C.J., Li X., Cai L., Cui T. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 2011, 60:625-633.
49. Tang J., Kern T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30:343-358.
50. Wang S., Gottlieb J.L., Sorenson C.M., Sheibani N. Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes. Arch. Ophthalmol. 2009, 127:507-513.
51. Wolburg H., Neuhaus J., Kniesel U., Krauss B., Schmid E.M., Ocalan M., Farrell C., Risau W. Modulation of tight junction structure in blood-brain barrier endothelial cells. Effects of tissue culture, second messengers and cocultured astrocytes. J. Cell Sci. 1994, 107(Pt 5):1347-1357.
52. Xiao K., Garner J., Buckley K.M., Vincent P.A., Chiasson C.M., Dejana E., Faundez V., Kowalczyk A.P. p120-Catenin regulates clathrin-dependent endocytosis of VE-cadherin. Mol. Biol. Cell 2005, 16:5141-5151.
53. Yamagishi S.-I., Matsui T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy - friend or foe?. Pharmacol. Res. 2011, 64:187-194.
54. Yuuki T., Kanda T., Kimura Y., Kotajima N., Tamura J., Kobayashi I., Kishi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J. Diabetes Complications 2001, 15:257-259.
55. Zhang W., Liu H., Al-Shabrawey M., Caldwell R.W., Caldwell R.B. Inflammation and diabetic retinal microvascular complications. J. Cardiovasc. Dis. Res. 2011, 2:96-103.
56. Zheng L., Kern T.S. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front. Biosci. 2009, 14:3974-3987.